CERo to Present at the Society of Immunotherapy for Cancer (SITC)
CERo Therapeutics to Present Data on Novel Engineered T Cell Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
First presentation of platform technology designed to expand the therapeutic potential of engineered T cell-based therapies.
South San Francisco, Calif. — October 25, 2021
CERo Therapeutics, Inc., a biopharmaceutical company pioneering the development of novel engineered immune cellular therapies, today announced the upcoming presentation of preclinical data describing the design, manufacture and in vitro characterization of novel chimeric engulfment receptor (CER) T cells at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2021), which is being held virtually and in person in Washington, D.C. from November 10-14, 2021.
“We are looking forward to sharing data describing our core technology platform with the scientific community at SITC,” said Daniel Corey, MD, founder and CEO of CERo. “As our technology continues to mature, we are increasingly encouraged by the orthogonal biology of CER T cells and their potential to overcome barriers to successful adoptive cell therapy.”
CERo’s technology aims to expand the therapeutic potential of engineered T cell-based therapies by introducing distinct and complementary tumor cell clearance pathways into single T cells. By engineering T cells to express CERs, CERo’s technology enables T cells to target tumors across multiple indications, induce cellular damage, engulf tumor fragments, display tumor antigens, and clear tumors, effectively harnessing the anti-tumor attributes of both innate and adaptive immune responses. CER T-cell products are designed to generate more complete and durable anti-tumor response. This novel biology amends itself to combinations with small molecule therapy or classic CAR T cell approaches and has potential applications across both hematologic malignancies and solid tumors.
Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells
Abstract number: 207
Date: Friday, November 12, 2021
About CERo Therapeutics
CERo Therapeutics, Inc. is a biopharmaceutical company pioneering a new class of cell-based therapies that combine attributes of the innate and adaptive arms of the immune system into single T cells. The integrated approach draws on recent advances in synthetic and T cell biology with the intent to improve upon and optimize cell therapy to increase the curative potential and safety profile of current approaches. CERo is advancing a pipeline of engineered CER T-cell products directed against hematologic malignancies and solid tumors. To learn more about the company and its science, please visit www.cero.bio.